Three Years In: What Oregon's Measure 109 Data Now Tells Clinicians About Real-World Psilocybin Services

Measure 109 is no longer an experiment. It is a three-year-old market with regulator-grade data, and that changes what referring clinicians need to understand. For the first time, a mental health practitioner asked by a patient about regulated psilocybin can answer with utilisation numbers rather than ideology.

What the data actually shows

The first complete dataset (full-year 2025 plus Q1 2026) was released under SB 303 quarterly reporting requirements, and Psychedelic Alpha's tracker integrates Oregon Health Authority filings from licensed service centres, facilitators and manufacturers. The headline is contraction-with-stabilisation: cumulative clients (~17,000) keep rising, but year-on-year client volume in 2025 (5,935) fell short of optimistic 2023 projections. The price decline (~$85 → ~$51 per product) is the predictable result of new manufacturers entering — but it has not been enough to offset the binding constraint, which is total session cost: facilitator time, service-centre overhead, mandated screening and post-session integration push the consumer-facing price into the $1,000–3,000 range.

The structural story is service-centre attrition. Of the 35 centres originally licensed, only about 23 remain operational; closures cluster among independent operators outside the Portland–Eugene corridor. The $10,000 annual licence fee, security-camera and storage-compliance costs, and the inability to bill insurance (psilocybin remains Schedule I federally) make break-even difficult below ~120 sessions per year per centre. Rural Oregon counties — most of which exercised the local opt-out provision baked into Measure 109 — produce a geographic access map that resembles abortion access more than primary care: dense in two metros, near-absent in 24 of 36 counties.

What this means for referring clinicians

For practitioners outside Oregon — and especially for clinicians whose patients ask about psychedelic options after reading Lykos / FDA news — the Oregon data clarifies what the non-medical-model version of legal psilocybin access actually looks like in practice. Three points matter for referral decisions and informed-consent discussions:

First, the Oregon model is adult use under facilitator supervision, not medical treatment. Service centres do not diagnose, do not prescribe, and are explicitly prohibited from claiming therapeutic indication. Clients self-select; intake screens for cardiac contraindications, current psychosis, recent SSRIs, lithium, and active suicidality, but there is no clinician of record. Patients with treatment-resistant depression or PTSD who travel to Oregon are not entering a clinical trial — they are buying a regulated experience. Counsel them accordingly.

Second, safety signal so far is reassuring at the population level, not at the individual level. Oregon's adverse-event reports across ~17,000 administrations have not produced the catastrophic outcomes that critics predicted; on the other hand, the dataset has known underreporting, lacks structured post-session follow-up, and cannot detect delayed psychiatric decompensation. Tell patients: "no signal of mass harm" is not "evidence of safety in your case."

Third, the federal-state gap matters more than the Oregon news cycle suggests. Lykos' FDA rejection in August 2024 and the company's 75% workforce cut in 2025 mean that an FDA-approved MDMA-AT or psilocybin-AT pathway is, at minimum, multiple years and another Phase 3 trial away. The Australian TGA Authorised Prescriber scheme has dosed ~200 patients in two years — Oregon's adult-use model has served roughly 85× that volume in roughly the same window. The two pathways are now empirically diverging, and the field is no longer waiting for the FDA to decide which model is "real."